Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Firefly’s groundbreaking BNA technology identifies brain age biomarker, potentially advancing early Alzheimer’s screening

Firefly Neuroscience (NASDAQ:AIFF) has announced the discovery of a novel biomarker capable of estimating the biological age of a patient’s brain through its FDA-cleared Brain Network Analytics (BNA) technology platform...

January 14, 2025

Developments

ORIC enters into clinical supply agreement with Janssen

ORIC Pharmaceuticals (NASDAQ:ORIC) has announced a supply agreement with Janssen Research & Development to evaluate ORIC-114, a brain penetrant, oral bioavailable, irreversible EGFR/HER2 inhibitor, in combination...

January 14, 2025

Developments

Adaptive partners with NeoGenomics to advance blood cancer monitoring

Adaptive Biotechnologies (NASDAQ:ADPT) and NeoGenomics (NASDAQ:NEO) have announced a multi-year exclusive collaboration aimed at advancing minimal residual disease (MRD) monitoring options for patients with select blood...

January 14, 2025

Developments

Clear Labs secures $30 million in series D financing to advance sequencing solutions; adds Kevin Keegan to BOD

Closely-held Clear Labs announced the successful completion of a $30 million series D financing round aimed at accelerating the development and adoption of its cutting-edge sequencing solutions. According to Clear Labs...

January 13, 2025

Developments

Biovica expands services with major TKa testing order

Biovica International (STO:BIOVIC-B; STO:BIOVIC.B; FRA:911) has announced the signing of a significant work order for TKa testing services, valued at 2.3 MSEK. The agreement has been made with a UK-based...

January 13, 2025

Developments

Arrivo unveils positive study results on SP-624’s impact on depression and cognition

Closely held Arrivo BioVentures has announced promising results from its study evaluating SP-624’s novel epigenetic mechanism of action on neurological pathways. According to the company, the findings provide insights...

January 10, 2025

Developments

FDA grants additional FTD to Mersana’s XMT-1660 for breast cancer

Mersana Therapeutics (NASDAQ:MRSN) has announced that the FDA has granted an additional fast track designation (FTD) to its emiltatug ledadotin (XMT-1660) for the treatment of advanced or metastatic breast cancer. The...

January 10, 2025

Developments

Genenta strengthens pact with CDMO to enhance production

Genenta Science (NASDAQ:GNTA) announced that it has amended its development and master services agreement with contract development and manufacturing organization (CDMO) AGC Biologics to bolster production capabilities...

January 10, 2025

Developments

Inspira responds to China’s recent hMPV outbreak; prepares to ramp up production

Inspira Technologies (NASDAQ:IINN) has announced its preparations for a possible increase in production of its INSPIRA ART100 device to address the growing demand for advanced respiratory care technologies following the...

January 10, 2025

Developments

Onco-Innovations’ technology aims to transform cancer treatments

Onco-Innovations (CSE:ONCO; FRANKFURT:W1H; WKN:A3EKSZ) has announced that its exclusively-licensed, patented polynucleotide kinase 3’-phosphates (PNKP) inhibitors technology holds the potential to significantly enhance...

January 9, 2025

Developments

MOBILion spotlights 100th peer-reviewed publication featuring its separations technology platform

Closely held MOBILion Systems has announced that, as of December 24, 2024, its foundational Structures for Lossless Ion Manipulation (SLIM) platform technology has been highlighted in 100 peer-reviewed publications in...

January 8, 2025

Developments

MediPharm expands Brazilian presence through agreement with Teuto

MediPharm Labs (TSX:LABS; OTCQX:MEDIF) has announced an agreement with Laboratório Teuto to expand its reach into the Brazilian medical cannabis market. The company states that it has been working closely with Teuto on...

January 8, 2025

Developments

FDA clears Solid’s IND application for SGT-212 in FA

Solid Biosciences (NASDAQ:SLBD) announced that the FDA has cleared its IND application for SGT-212, a first-in-industry dual-route of administration gene therapy designed to treat the neurologic and cardiac...

January 8, 2025

Developments

CytoMed and SunAct sign agreement for solid tumor treatment trial in India

CytoMed Therapeutics (NASDAQ:GDTC) has announced the signing of a five-year business and research collaboration agreement with the SunAct Cancer Institute to investigate the efficacy, safety, tolerability, and potency...

January 7, 2025

Developments

OraSure’s HIV Self-Test approved for adolescents

OraSure Technologies (NASDAQ:OSUR) has announced that the approved age range for its OraQuick HIV Self-Test has been expanded to include individuals aged 14 and older. The company cites data from the Centers for Disease...

January 7, 2025

Developments

Portage relaunches independent subsidiary with Peter Molloy as CEO

Portage Biotech (NASDAQ:PRTG) has announced the relaunch of its wholly-owned adenosine subsidiary, Cyncado Therapeutics, as an independently managed company headed by Peter Molloy as CEO. The company reports that...

January 6, 2025

Developments

Santhera inks exclusive distribution deal with Clinigen for AGAMREE in DMD

Santhera Pharmaceuticals (SIX:SANN) and closely held Clinigen Group have announced the signing of a supply and distribution agreement that will make AGAMREE accessible to patients with Duchene muscular dystrophy (DMD)...

January 6, 2025

Developments

Clearmind granted patent for binge behavior treatment in Macau

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) has announced that its proprietary MEAI-based binge behavior regulator program has received patent approval from the Macau International Intellectual Property Office, a special...

January 3, 2025

Developments

Eton acquires rare disease product Galzin

Eton Pharmaceuticals (NASDAQ:ETON) has announced the acquisition of Galzin, a rare disease product used in the treatment of Wilson disease. The company reports that Galzin, an FDA-approved zinc acetate, is utilized as a...

January 3, 2025

Developments

Japan approves SIGA’s antiviral for orthopoxvirus

SIGA Technologies (NASDAQ:SIGA) has announced that its product, TEPOXX, an antiviral therapy targeting orthopoxviruses, has received approval from Japan’s Pharmaceuticals and Medical Devices Agency and the Japan...

January 3, 2025

Developments

Oruka initiates dosing of first patient in Phase 1 trial of ORKA-001

Oruka Therapeutics (NASDAQ:ORKA) has announced the initiation of dosing of in its Phase 1 clinical trial of ORKA-001, a subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Inhibitors...

December 20, 2024

Developments

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

Silo Pharma (NASDAQ:SILO) has announced the initiation of a preclinical pharmacokinetic (PK) and tolerability study, in partnership with AmplifyBio, to assess Silo’s dissolvable, ketamine-based injectable implant, SP-26...

December 18, 2024

Subscribe